Chinese radiotherapy market opens up for Sensus following approval for platform technology
Sensus Healthcare and Megatop MTC have secured SFDA approval for its SRT-100 advanced superficial radiotherapy platform to be sold in China. The platform offers an alternative to surgical procedures for basal cell and squamous cell carcinomas. The SRT-100 systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.
Following this approval allows Megatop MTC to begin their sales and marketing initiatives in China immediately. Megatop has already ordered nine systems to be delivered in 2012 to meet the existing demand. This is a continuation to the initial launch started by Megatop MTC in Hong Kong, where they have sold and installed two SRT-100 units at the Prince of Wales and Sanatorium hospitals, respectively.